Covering the operations of the oil and gas industry
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
Sections
General Interest
Refining & Processing
Drilling & Production
Exploration & Development
Pipelines & Transportation
LNG
Energy Transition
Industry Statistics
Members Only
Special
Webcasts
White Papers
Podcast
Magazine
Surveys
Research
Events
Submit an Article
Iran war
Contact
About Us
Subscribe
Newsletters
Advertise
Contact Us
Privacy Policy
Terms & Conditions
Affiliated Brands
OFFSHORE
ENERGYTECH
MICROGRID KNOWLEDGE
OGJ RESEARCH
Follow us on
http://www.facebook.com/ogjonline
https://www.linkedin.com/company/oil-&-gas-journal
http://twitter.com/ogjonline
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
PennEnergy Stock Watch
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Oculis Holding AG - Ordinary shares
(NQ:
OCS
)
12.56
-1.95 (-13.44%)
Streaming Delayed Price
Updated: 3:47 PM EDT, Jun 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Oculis Holding AG - Ordinary shares
< Previous
1
2
Next >
Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema
May 29, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors
May 14, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q1 2026 Financial Results and Provides Company Update
May 11, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
May 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting
May 05, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present at Upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 01, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Invitation to the Annual General Meeting
April 21, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Completion of Last Patient Visit in Phase 3 DIAMOND Program with OCS-01 Eye Drops for the Treatment of Diabetic Macular Edema
April 20, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming Investor Conferences
April 07, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‑in‑Class Neuroprotective Candidate for Optic Neuritis
March 31, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present at Upcoming North American Neuro-Ophthalmology Society Annual Meeting
March 16, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming Investor Conferences
March 05, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q4 and Full Year 2025 Financial Results and Provides Company Update
March 03, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Appoints Katie Kazem as Chief Legal Officer
February 17, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Showcase Transformative Late-stage Pipeline in Neuro-ophthalmology and Ophthalmology at the 2026 J.P. Morgan Healthcare Conference
January 08, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces U.S. FDA Breakthrough Therapy Designation Granted to Privosegtor for Treatment of Optic Neuritis
January 06, 2026
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q3 2025 Financial Results and Provides Company Update
November 10, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming November Investor Conferences
November 05, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Oversubscribed $110 Million Financing to Accelerate Privosegtor Development
October 30, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Spotlight Transformative Late-Stage Pipeline at Eyecelerator and AAO 2025
October 14, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Accelerates Privosegtor into Registrational Trials in Acute Optic Neuritis, Pioneering the Path for a Potential First-in-class Neuroprotective Therapy
October 06, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
September 22, 2025
Privosegtor ACUITY Trial showed Improved LCVA and preservation of Ganglion Cells in Acute Optic Neuritis. Results from a Multicenter Randomized Placebo-Controlled Double-Masked Trial
From
Oculis Holding AG
Via
GlobeNewswire
Oculis and EURETINA Announce the Winner of the Ramin Tadayoni Award 2025
September 04, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
September 01, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming September Investor Conferences
August 28, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Appoints Mark Kupersmith, M.D., and Sebastian Wolf, M.D., Ph.D., World-Renowned Neuro-Ophthalmology and Retina Experts, as Chief Medical Advisors
August 25, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Reports Q2 2025 Financial Results and Provides Company Update
August 21, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis to Participate in Upcoming H.C. Wainwright 5th Annual Ophthalmology Virtual Conference
August 12, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Upsized Loan Facility to Access up to CHF 100 million
August 01, 2025
From
Oculis Holding AG
Via
GlobeNewswire
Oculis Publishes Results of 2025 Annual General Meeting
June 05, 2025
From
Oculis Holding AG
Via
GlobeNewswire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
